ES2570135T3 - Sal y solvatos de un derivado de tetrahidroisoquinolina - Google Patents

Sal y solvatos de un derivado de tetrahidroisoquinolina

Info

Publication number
ES2570135T3
ES2570135T3 ES11740973T ES11740973T ES2570135T3 ES 2570135 T3 ES2570135 T3 ES 2570135T3 ES 11740973 T ES11740973 T ES 11740973T ES 11740973 T ES11740973 T ES 11740973T ES 2570135 T3 ES2570135 T3 ES 2570135T3
Authority
ES
Spain
Prior art keywords
solvates
salt
tetrahydroisoquinoline derivative
tetrahydroisoquinoline
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11740973T
Other languages
English (en)
Inventor
Thomas David Mccarthy
Peter Michael Kelly
Craig James Stewart Boyle
Alexander Redvers Eberlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2570135T3 publication Critical patent/ES2570135T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Sal de sodio del ácido (S)-2-(difenilacetil)-1,2,3,4-tetrahidro-6-metoxi-5-(fenilmetoxi)-3-isoquinolin-carboxílico y solvatos del mismo, en forma amorfa o en forma de un solvato cristalino.
ES11740973T 2010-07-21 2011-07-21 Sal y solvatos de un derivado de tetrahidroisoquinolina Active ES2570135T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36636710P 2010-07-21 2010-07-21
PCT/GB2011/001096 WO2012010843A1 (en) 2010-07-21 2011-07-21 Salt and solvates of a tetrahydroisoquinoline derivative

Publications (1)

Publication Number Publication Date
ES2570135T3 true ES2570135T3 (es) 2016-05-17

Family

ID=44386640

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11740973T Active ES2570135T3 (es) 2010-07-21 2011-07-21 Sal y solvatos de un derivado de tetrahidroisoquinolina

Country Status (20)

Country Link
US (3) US8614227B2 (es)
EP (2) EP2595960B1 (es)
JP (3) JP5948326B2 (es)
CN (2) CN103003244B (es)
AU (3) AU2011281381B2 (es)
CA (1) CA2803699C (es)
DK (1) DK2595960T3 (es)
ES (1) ES2570135T3 (es)
HK (1) HK1224290A1 (es)
HR (1) HRP20160540T1 (es)
HU (1) HUE028620T2 (es)
ME (1) ME02407B (es)
NZ (2) NZ605444A (es)
PL (1) PL2595960T3 (es)
PT (1) PT2595960E (es)
RS (1) RS54789B1 (es)
SI (1) SI2595960T1 (es)
SM (1) SMT201600171B (es)
WO (1) WO2012010843A1 (es)
ZA (1) ZA201300169B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ605444A (en) * 2010-07-21 2015-06-26 Spinifex Pharm Pty Ltd Salt and solvates of a tetrahydroisoquinoline derivative
US9320530B2 (en) * 2013-03-13 2016-04-26 The Spectranetics Corporation Assisted cutting balloon
NZ630908A (en) * 2013-07-08 2017-08-25 Novartis Ag Heterocyclic compounds and methods of their use
CN107001337B (zh) 2015-01-13 2021-05-04 诺华股份有限公司 作为血管紧张素ii型拮抗剂的吡咯烷衍生物
ES2898635T3 (es) 2015-03-12 2022-03-08 Novartis Ag Compuestos heterocíclicos y métodos para su uso
CN106478502B (zh) * 2015-08-29 2021-04-27 上海翰森生物医药科技有限公司 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
EP3475261A1 (en) 2016-06-27 2019-05-01 ratiopharm GmbH Crystalline calcium salt of (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid
WO2018172950A1 (en) * 2017-03-23 2018-09-27 Novartis Ag Anhydrous crystalline forms of sodium (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinolinecarboxylate
KR102132761B1 (ko) * 2017-06-09 2020-07-17 산동 단홍 파머수티컬 컴퍼니., 리미티드. At2r 수용체 길항제로서의 카르복시산 유도체
WO2020012266A1 (en) 2018-07-12 2020-01-16 Novartis Ag Biocatalytic synthesis of olodanrigan (ema401) from 3-(2-(benzyloxy)-3-methoxyphenyl)propenoic acid with phenylalanine ammonia lyase
EP3820833A4 (en) 2018-07-12 2022-08-03 Codexis, Inc. MODIFIED AMMONIA-LYASE PHENYLALANINE POLYPEPTIDES
CN111620816B (zh) * 2020-05-27 2023-06-02 上海赛默罗生物科技有限公司 螺桨烷类衍生物、其制备方法、药物组合物和用途
GB202100352D0 (en) * 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods
CN115901740A (zh) * 2022-11-18 2023-04-04 南京工业大学 基于Pictet-Spengler反应的多巴胺检测试剂及应用、多巴胺的检测方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
AU747110B2 (en) * 1998-02-25 2002-05-09 Merck & Co., Inc. Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist
NZ555334A (en) * 2004-12-24 2010-05-28 Spinifex Pharm Pty Ltd Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist
JP5230595B2 (ja) 2006-03-20 2013-07-10 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド 炎症性疼痛の治療または予防の方法
ES2560327T3 (es) * 2010-01-19 2016-02-18 Novartis Ag Métodos y composiciones para una velocidad de conducción nerviosa mejorada
NZ605444A (en) * 2010-07-21 2015-06-26 Spinifex Pharm Pty Ltd Salt and solvates of a tetrahydroisoquinoline derivative

Also Published As

Publication number Publication date
AU2011281381B2 (en) 2015-07-16
AU2015238774A1 (en) 2015-10-29
CN105777636A (zh) 2016-07-20
US8927575B2 (en) 2015-01-06
HRP20160540T1 (hr) 2016-06-17
ZA201300169B (en) 2016-03-30
JP2017214415A (ja) 2017-12-07
JP5948326B2 (ja) 2016-07-06
NZ708529A (en) 2016-11-25
ME02407B (me) 2016-09-20
PL2595960T3 (pl) 2016-09-30
CA2803699A1 (en) 2012-01-26
NZ605444A (en) 2015-06-26
DK2595960T3 (en) 2016-05-09
HUE028620T2 (en) 2016-12-28
RS54789B1 (sr) 2016-10-31
EP2595960B1 (en) 2016-02-24
JP2016164178A (ja) 2016-09-08
CN103003244B (zh) 2016-04-20
AU2017203236A1 (en) 2017-06-08
SMT201600171B (it) 2016-07-01
JP2013531057A (ja) 2013-08-01
US20150105422A1 (en) 2015-04-16
US20120022101A1 (en) 2012-01-26
EP2595960A1 (en) 2013-05-29
WO2012010843A1 (en) 2012-01-26
US20140080865A1 (en) 2014-03-20
CA2803699C (en) 2016-05-31
EP3081557A1 (en) 2016-10-19
HK1224290A1 (en) 2017-08-18
US9162985B2 (en) 2015-10-20
AU2011281381A1 (en) 2013-01-10
SI2595960T1 (sl) 2016-06-30
PT2595960E (pt) 2016-06-02
US8614227B2 (en) 2013-12-24
CN103003244A (zh) 2013-03-27

Similar Documents

Publication Publication Date Title
NO2020018I1 (no) Darolutamide, optionally in the form of a pharmaceutically acceptable salt or ester thereof
AR117799A2 (es) Sal(es) de dimetil-amida del ácido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]-pirimidin-6-carboxílico y procesos para su elaboración
EP2718731A4 (en) IMPACT INDICATOR
MX372691B (es) Pirrolobenzodiazepinas y conjugados de las mismas.
IL246133A0 (en) A sulfonamide derivative or their pharmaceutically acceptable acid addition salts
EP2561540A4 (en) IMPROVED ION SOURCE
PH12015501439A1 (en) Oral care products comprising zinc oxide and trimethylglycine
PE20160605A1 (es) Formulaciones de inhibidores de la syk
MY165215A (en) Pyridone derivatives
EP2881384A8 (en) Partially saturated nitrogen-containing heterocyclic compound
UY34503A (es) ?sal de bromhidrato de pridopidina?
IT1402907B1 (it) Composizioni topiche per mantenere o ripristinare l'integrita' delle mucose.
PH12013500449A1 (en) Treatment of diseases
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
UY32535A (es) Métodos e intermediarios para la preparación de agentes farmacéuticos
NZ605444A (en) Salt and solvates of a tetrahydroisoquinoline derivative
GB201101517D0 (en) Receptor antagonists
BR302013000613S1 (pt) "configuração aplicada em para-choque dianteiro"
BRPI1014821A2 (pt) "inibidores de replicação de hiv"
MY149154A (en) Novel microbiocides
PH12015500012B1 (en) Benzodioxole derivative and preparation method and use thereof
MX2015015755A (es) Derivados de perhidroquinoxalina utiles como analgesicos.
PH12015501146A1 (en) Hydantoin derivative
EA201391586A1 (ru) ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
FR2957225B1 (fr) Procede d'elevage de coquillages, notamment des huitres.